Dihydromyricetin as an IKK-beta Inhibitor Used for Treatment of Arthritis, Cancer and Autoimmune Conditions
- Summary
- Use of dihydromyricetin (DMY) as an NF-κB inhibitor or an IKK-β inhibitor for the treatment of arthritis, cancer, autoimmune conditions and other disease is provided. A pharmaceutical composition comprising DMY is also provided.
- Technology Benefits
- Administrating a therapeutically effective amount of an immunosuppressive compound, i.e. DMY, to a subject in need.
- Technology Application
- For the treatment of autoimmune conditions, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, cancer, diabetes mellitus, neurodegenerative disease, immunological disorder, hypersensitivity, and arthritis.
- Detailed Technology Description
- The use of the compound is dihydromyricetin (DMY), which is an NF-κB inhibitor. DMY, characterized as a flavonoid, is the major bioactive constituent of Amplopsis grossedentata.
- Supplementary Information
- Inventor: LIU, Liang | ZHOU, Hua | LI, Ting | WONG, Kam Wai | JIANG, Zhi Hong
Priority Number: US20120053235A1
IPC Current: A61K003135 | A61P000104 | A61P000310 | A61P000514 | A61P000702 | A61P000706 | A61P001100 | A61P001106 | A61P001700 | A61P001706 | A61P001902 | A61P001904 | A61P001906 | A61P002514 | A61P002516 | A61P002528 | A61P002900 | A61P003500 | A61P003700 | A61P003706 | A61P003708
US Class: 514456
Assignee Applicant: Hong Kong Baptist University
Title: Dihydromyricetin as an IKK-beta inhibitor used for treatment of arthritis, cancer and autoimmune conditions, and other diseases or disorders
Usefulness: Dihydromyricetin as an IKK-beta inhibitor used for treatment of arthritis, cancer and autoimmune conditions, and other diseases or disorders
Summary: The method is useful for treating: autoimmune disease; rheumatoid arthritis; chronic obstructive pulmonary disease; asthma; cancer; diabetes mellitus; neurodegenerative disease including Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, ataxia telangiectasia, spinocerebellar atrophy, multiple sclerosis, or Huntington's chorea; immunological disorder including allergic rhinitis, allergic dermatitis, allergic contact dermatitis, allergic shock, papular urticaria, leucoderma, hypersensitivity vasculitis, hypersensitivity pneumonia, ulcerative colitis, glomerulonephritis, drug rashes, systemic lupus erythematosus, scleroderma, hyperthyroidism, idiopathic thrombocytopenic, autoimmune hemolytic anemia, allograft rejection, or hemolytic transfusion reaction; or arthritic disorder including ankylosing spondylitis, gout, periarthritis, osteoarthritis, Reiter syndrome, psoriatic arthritis, post-traumatic arthritis, or enteropathic arthritis (all claimed). Tests details are described but no results given.
Novelty: Treating autoimmune disease, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, cancer, diabetes mellitus, neurodegenerative disease, immunological disorder, or arthritic disorder comprises administering dihydromyricetin
- Industry
- Disease Diagnostic/Treatment
- Sub Category
- Cancer/Tumor
- Application Date
- 2011.08.30
- Application No.
- US 13/197,768
- Others
- Filed
- ID No.
- A61/LL/Dihy/US01
- Country/Region
- Hong Kong
For more information, please click Here
